

(19) 世界知的所有権機関  
国際事務局(43) 国際公開日  
2004 年 5 月 21 日 (21.05.2004)

PCT

(10) 国際公開番号  
WO 2004/041850 A1(51) 国際特許分類<sup>7</sup>: C07K 7/08,  
A61K 38/10, C07K 16/18, A61K 39/395

(21) 国際出願番号: PCT/JP2003/014138

(22) 国際出願日: 2003 年 11 月 6 日 (06.11.2003)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:  
特願2002-324189 2002 年 11 月 7 日 (07.11.2002) JP  
特願 2002-367119  
2002 年 12 月 18 日 (18.12.2002) JP  
特願2003-59073 2003 年 3 月 5 日 (05.03.2003) JP  
特願2003-191359 2003 年 7 月 3 日 (03.07.2003) JP(71) 出願人 (米国を除く全ての指定国について): 武田薬品  
工業株式会社 (TAKEDA CHEMICAL INDUSTRIES,  
LTD.) [JP/JP]; 〒541-0045 大阪府 大阪市中央区 道修  
町四丁目 1 番 1 号 Osaka (JP).

(72) 発明者; および

(75) 発明者/出願人 (米国についてのみ): 日沼 州司  
(HINUMA, Shuji) [JP/JP]; 〒305-0821 茨城県 つくば  
市 春日 1 丁目 7-9-1 4 0 2 Ibaraki (JP). 小林 真  
(KOBAYASHI, Makoto) [JP/JP]; 〒651-2276 兵庫県 神  
戸市西区 春日台七丁目 5-5 Hyogo (JP). 羽畑 祐吾  
(HABATA, Yugo) [JP/JP]; 〒305-0044 茨城県 つくば  
市 並木 3 丁目 1 7-1-6 0 6 Ibaraki (JP). 原田 征  
隆 (HARADA, Masataka) [JP/JP]; 〒305-0046 茨城県  
つくば市 東 2 丁目 1 4-5-2 0 1 Ibaraki (JP). 大久  
保 尚一 (OKUBO, Shoichi) [JP/JP]; 〒300-1234 茨城県 牛久市 中央 1 丁目 4-2 3 Ibaraki (JP). 吉田 博美  
(YOSHIDA, Hiromi) [JP/JP]; 〒300-2741 茨城県 結城  
郡 石下町 大字 国生 1 4 4 4-2 3 Ibaraki (JP). 西 一  
紀 (NISHI, Kazunori) [JP/JP]; 〒305-0044 茨城県 つく  
ば市 並木 4 丁目 1 6-1-4 0 2 Ibaraki (JP).(74) 代理人: 高橋 秀一, 外 (TAKAHASHI, Shuichi et al.);  
〒532-0024 大阪府 大阪市淀川区 十三本町 2 丁目  
1 7 番 8 5 号 武田薬品工業株式会社大阪工場内 Os-  
aka (JP).(81) 指定国 (国内): AE, AG, AL, AM, AT, AU, AZ, BA, BB,  
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,  
DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.(84) 指定国 (広域): ARIPO 特許 (BW, GH, GM, KE, LS,  
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア特  
許 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッ  
パ特許 (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
TR), OAPI 特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).添付公開書類:  
— 国際調査報告書2 文字コード及び他の略語については、定期発行される  
各 PCT ガゼットの巻頭に掲載されている「コードと略語  
のガイダンスノート」を参照。

(54) Title: NOVEL FPRL1 LIGANDS AND USE THEREOF

(54) 発明の名称: 新規な FPRL1 リガンドおよびその用途

(57) Abstract: By using an FPRL1 ligand having an amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:17 or SEQ ID NO:21 together with FPRL1, an FPRL1 agonist or an FPRL1 antagonist can be efficiently screened.

(57) 要約: 配列番号: 1、配列番号: 17 または配列番号: 21 で表わされるアミノ酸配列と同一もしくは実質的に同一のアミノ酸配列を含有する FPRL1 リガンドと FPRL1 を用いることにより、FPRL1 アゴニストまたは FPRL1 アンタゴニストを効率良くスクリーニングすることができる。



WO 2004/041850 A1



# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/JP03/14138

## A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl<sup>7</sup> C07K7/08, A61K38/10, C07K16/18, A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> C07K7/08, A61K38/10, C07K16/18, A61K39/395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Registry (STN), WPIDS/BIOSIS/BIOTECHABS/MEDLINE/CA (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> A	ANDERSON S. et al., Sequence and organization of the human mitochondrial genome, Nature, 1981, Vol.290, pages 457 to 465	<u>15</u> 1-5, 10, 12-14, 17, 19, 20, 22-24, 26, 27, 59, 61
A	LE Y. et al., Formyl-peptide receptors revisited, Trends Immunol., 01 November, 2002 (01.11.02), Vol.23, pages 541 to 548	1-5, 10, 12-15, 17, 19, 20, 22-24, 26, 27, 59, 61

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
04 February, 2004 (04.02.04)

Date of mailing of the international search report  
17 February, 2004 (17.02.04)

Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/JP03/14138

## Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 58, 60  
because they relate to subject matter not required to be searched by this Authority, namely:  
These claims pertain to methods for treatment of the human body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The peptides as set forth in claims 1 and 6 are common to each other not in chemical structure but exclusively in being an endogenous ligand of FPRL1.

However, endogenous ligands of FPRL1 are publicly known as reported in document Int. Immunopharmacol., 2002, Vol.2, p.1, etc. Therefore, this common matter is not regarded as a special technical feature within the meaning of the second sentence in PCT Rule 13.2. There is no other common matter between the peptides as claimed in claims 1 and 6 seemingly being a special technical feature within the meaning of the second sentence in PCT Rule 13.2. (Continued to extra sheet.)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
Claims 1 to 5, 10, 15, 17, 20, 24 and 27 and the parts depending on claims 1 to 5 in claims 12 to 14, 19, 22, 23, 26, 59 and 61.

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Continuation of Box No.II of continuation of first sheet(1)

The peptides as set forth in claims 1 and 29 are common to each other not in chemical structure but exclusively in being a peptide relating to FPRL1.

However, peptides relating to FPRL1 are publicly known as reported in document J. Biol. Chem., 1992, Vol.267, p.7637, document Int. Immunopharmacol., 2002, Vol.2, p.1, etc. Therefore, this common matter is not regarded as a special technical feature within the meaning of the second sentence in PCT Rule 13.2. There is no other common matter between the peptides as claimed in claims 1 and 29 seemingly being a special technical feature within the meaning of the second sentence in PCT Rule 13.2.

The same applies to claims 6 and 29.

Such being the case, the inventions as set forth in the present case are not considered as relating to a group of inventions so linked as to form a single general inventive concept. Thus it is recognized that there are 3 groups of inventions in the present case.

**THIS PAGE BLANK (USPTO)**